JP2020509093A - 遺伝子工学菌vnp20009−mの肺癌予防・治療薬の製造における応用 - Google Patents
遺伝子工学菌vnp20009−mの肺癌予防・治療薬の製造における応用 Download PDFInfo
- Publication number
- JP2020509093A JP2020509093A JP2019569533A JP2019569533A JP2020509093A JP 2020509093 A JP2020509093 A JP 2020509093A JP 2019569533 A JP2019569533 A JP 2019569533A JP 2019569533 A JP2019569533 A JP 2019569533A JP 2020509093 A JP2020509093 A JP 2020509093A
- Authority
- JP
- Japan
- Prior art keywords
- lung cancer
- plasmid
- vnp20009
- application according
- methioninase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/42—Salmonella
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
臨床で、73歳の男性患者は、胸腔鏡下手術を用いた右下葉扁平上皮癌の根治手術を受けてから5か月間後、頸部に新しい腫瘍塊を発見され(図4参照)、測定した後、頸部での病巣の大きさは、約8cm×9cmであった。腫瘍塊部位の生検について細胞スミアを経って、癌細胞と同定され(図5参照)、そして骨ECTは、複数箇所の活発な骨代謝を示し、胸部CT検査では、腫瘍塊形成を伴う胸骨破壊が報告された。
3.1 病巣の大きさの変化
治療前に頸部での病巣の腫瘍塊を測定したところ、そのサイズは、約8cm×9cmであった(図4参照)。3週間の治療後、腫瘍塊は明らかに減少した(図6参照)。5週間の治療後(5回目の治療終了)、腫瘍塊は消えた(図7参照)。12週間の治療後、頸部の鎖骨、すなわち原病巣部位には異常な変化は認めなかった(図8参照)。
治療前に、腫瘍塊の内部は嚢胞構造であったが、細胞学的スミアを解析したところ、多数の重度異形細胞、すなわち腫瘍細胞が確認された(参照図5)。
毎回治療の当日、注射9−10時間後で、患者が約38度に発熱し、物理的手段で降温すると体温を正常に回復することができる。当日には、約10分間、吐き気や嘔吐を伴った。それ以外は、他の異常な感覚はなかった。治療中、肝機能及び腎機能の指標を検査して、結果を以下の表2に示した。結果から分かるように、患者の肝機能及び腎機能の各指標が正常範囲にあった。以上の結果から分かるように、VNP20009−Mには人体に対する明らかな毒性がなかった。
Claims (10)
- 遺伝子工学菌VNP20009−Mの肺癌予防・治療薬の製造における応用。
- 前記肺癌は、原発性肺腫瘍、肺癌術後再発腫瘍及び肺癌転移腫瘍を含むことを特徴とする請求項1に記載の応用。
- 前記肺癌は、非小細胞肺癌及び小細胞肺癌を含むことを特徴とする請求項1又は2に記載の応用。
- 前記非小細胞肺癌は、扁平上皮癌、腺癌、腺扁平上皮癌、大細胞肺癌又は未分化癌を含むことを特徴とする請求項3に記載の応用。
- 前記遺伝子工学菌VNP20009−Mの最小有効投与量は3.5*107CFU/M2であることを特徴とする請求項1−4のいずれか1項に記載の応用。
- 前記遺伝子工学菌VNP20009−Mの投与方式は、経口投与、局所投与、注射投与を含むことを特徴とする請求項1−5のいずれか1項に記載の応用。
- 前記遺伝子工学菌VNP20009−Mは、L−メチオニナーゼ遺伝子がクローニングされた弱毒ネズミチフス菌VNP20009であることを特徴とする請求項1−6のいずれか1項に記載の応用。
- 前記遺伝子工学菌VNP20009−Mは、L−メチオニナーゼ遺伝子がクローニングされたプラスミドを有する弱毒ネズミチフス菌VNP20009であることを特徴とする請求項7に記載の応用。
- 前記プラスミドは、pSVSPORTプラスミド、pTrc99Aプラスミド、pcDNA3.1プラスミド、pBR322プラスミド又はpET23aプラスミドを含むことを特徴とする請求項8に記載の応用。
- 前記遺伝子工学菌VNP20009−Mは、L−メチオニナーゼ遺伝子をプラスミドにサブクローニングして、L−メチオニナーゼ発現プラスミドを得て、L−メチオニナーゼ発現プラスミドを弱毒ネズミチフス菌VNP20009に電気的形質転換する方法によって構築されることを特徴とする請求項7−9のいずれか1項に記載の応用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710213446.6 | 2017-04-01 | ||
CN201710213446.6A CN106913883A (zh) | 2017-04-01 | 2017-04-01 | 基因工程菌vnp20009‑m在制备预防和治疗肺癌药物中的应用 |
PCT/CN2018/081115 WO2018177374A1 (zh) | 2017-04-01 | 2018-03-29 | 基因工程菌vnp20009-m在制备预防和治疗肺癌药物中的应用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020509093A true JP2020509093A (ja) | 2020-03-26 |
JP2020509093A5 JP2020509093A5 (ja) | 2020-05-07 |
JP6973737B2 JP6973737B2 (ja) | 2021-12-01 |
Family
ID=59567274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019569533A Active JP6973737B2 (ja) | 2017-04-01 | 2018-03-29 | 遺伝子工学菌vnp20009−mの肺癌予防・治療薬の製造における応用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US11771721B2 (ja) |
EP (1) | EP3586877A4 (ja) |
JP (1) | JP6973737B2 (ja) |
KR (1) | KR20200016836A (ja) |
CN (1) | CN106913883A (ja) |
AU (1) | AU2018241656B2 (ja) |
CA (1) | CA3056292C (ja) |
WO (1) | WO2018177374A1 (ja) |
ZA (1) | ZA201906222B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106913883A (zh) | 2017-04-01 | 2017-07-04 | 广州华津医药科技有限公司 | 基因工程菌vnp20009‑m在制备预防和治疗肺癌药物中的应用 |
CN112245573A (zh) * | 2020-10-16 | 2021-01-22 | 广东工业大学 | 减毒鼠伤寒沙门氏菌的基因工程菌在制备治疗癌症的药物上的应用 |
CN112190717B (zh) * | 2020-10-16 | 2023-12-15 | 广州华津医药科技有限公司 | 减毒鼠伤寒沙门氏菌及其基因工程菌在制备治疗急性白血病的药物上的应用 |
CN114712403B (zh) * | 2022-03-27 | 2024-05-17 | 江苏靶标生物医药研究所有限公司 | 一种减毒沙门氏菌在制备治疗肺癌胸腔积液药物中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150376593A1 (en) * | 2013-02-28 | 2015-12-31 | Nanjing Sinogen Biotech & Pharmaceutical Inc. | Genetically engineered bacterium for treatment of breast cancer, method for constructing the bacterium, and applications thereof |
WO2016145974A1 (zh) * | 2015-03-17 | 2016-09-22 | 南京华贞生物医药科技有限公司 | 基因工程菌vnp20009-m在制备预防和治疗癌症转移的药物上的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103961721B (zh) * | 2014-04-30 | 2018-10-23 | 广州华津医药科技有限公司 | 减毒鼠伤寒沙门氏菌及其基因工程菌在制备治疗前列腺癌的药物上的应用 |
CN106474489B (zh) * | 2015-08-31 | 2019-08-16 | 广州华津医药科技有限公司 | 减毒鼠伤寒沙门氏菌基因工程菌在制备治疗肝癌药物上的应用 |
CN106913883A (zh) * | 2017-04-01 | 2017-07-04 | 广州华津医药科技有限公司 | 基因工程菌vnp20009‑m在制备预防和治疗肺癌药物中的应用 |
-
2017
- 2017-04-01 CN CN201710213446.6A patent/CN106913883A/zh active Pending
-
2018
- 2018-03-29 US US16/497,820 patent/US11771721B2/en active Active
- 2018-03-29 JP JP2019569533A patent/JP6973737B2/ja active Active
- 2018-03-29 CA CA3056292A patent/CA3056292C/en active Active
- 2018-03-29 AU AU2018241656A patent/AU2018241656B2/en active Active
- 2018-03-29 WO PCT/CN2018/081115 patent/WO2018177374A1/zh unknown
- 2018-03-29 EP EP18777423.7A patent/EP3586877A4/en active Pending
- 2018-03-29 KR KR1020197032449A patent/KR20200016836A/ko not_active IP Right Cessation
-
2019
- 2019-09-19 ZA ZA2019/06222A patent/ZA201906222B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150376593A1 (en) * | 2013-02-28 | 2015-12-31 | Nanjing Sinogen Biotech & Pharmaceutical Inc. | Genetically engineered bacterium for treatment of breast cancer, method for constructing the bacterium, and applications thereof |
WO2016145974A1 (zh) * | 2015-03-17 | 2016-09-22 | 南京华贞生物医药科技有限公司 | 基因工程菌vnp20009-m在制备预防和治疗癌症转移的药物上的应用 |
Also Published As
Publication number | Publication date |
---|---|
AU2018241656A1 (en) | 2019-10-10 |
AU2018241656B2 (en) | 2020-10-29 |
EP3586877A4 (en) | 2020-04-15 |
CA3056292A1 (en) | 2018-10-04 |
KR20200016836A (ko) | 2020-02-17 |
ZA201906222B (en) | 2021-03-31 |
JP6973737B2 (ja) | 2021-12-01 |
EP3586877A1 (en) | 2020-01-01 |
CA3056292C (en) | 2023-01-24 |
US11771721B2 (en) | 2023-10-03 |
US20200023019A1 (en) | 2020-01-23 |
CN106913883A (zh) | 2017-07-04 |
WO2018177374A1 (zh) | 2018-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020509093A (ja) | 遺伝子工学菌vnp20009−mの肺癌予防・治療薬の製造における応用 | |
US9816083B2 (en) | Genetically engineered bacterium for treatment of breast cancer, method for constructing the bacterium, and applications thereof | |
US11318172B2 (en) | Use of genetically engineered bacterium of attenuated Salmonella typhimurium in for treating liver cancer | |
CN111420030B (zh) | Fgf21在制备用于治疗结直肠癌药物中的应用 | |
Zhang et al. | Retracted: long noncoding RNA MT1JP inhibits proliferation, invasion, and migration while promoting apoptosis of glioma cells through the activation of PTEN/Akt signaling pathway | |
Chen et al. | Knocking out SST gene of BGC823 gastric cancer cell by CRISPR/Cas9 enhances migration, invasion and expression of SEMA5A and KLF2 | |
Han et al. | RBM23 Drives Hepatocellular Carcinoma by Activating NF‐κB Signaling Pathway | |
Jiang et al. | Colon cancer-induced interleukin-35 inhibits beta-catenin-mediated pro-oncogenic activity | |
Cha et al. | Effect of perioperative treatment with a hypoxia-inducible factor-1-alpha inhibitor in an orthotopic surgical mouse model of thyroid cancer | |
WO2023072215A1 (zh) | 非小细胞肺癌靶点arid1a及其抑制剂在制备肺癌治疗药物中的用途 | |
KR102344837B1 (ko) | 악성 육종을 치료하기 위한 약물의 제조에서 유전적으로 조작된 박테리아 vnp20009-m의 응용 | |
CN113528528B (zh) | 一种促进耐伊马替尼慢性髓细胞白血病细胞K562/G01凋亡shRNA及其应用 | |
CN115998887A (zh) | 一种结直肠癌合成致死基因对的应用 | |
CN104721838B (zh) | Yap抑制剂在制备抗肿瘤药物中的应用 | |
US9439934B1 (en) | Application of an attenuated salmonella typhimurium, its genetically engineered bacterium in preparing drugs for the treatment of prostate cancer | |
CN111297871A (zh) | 一种百部生物碱类似物的应用 | |
CN104004831B (zh) | Kin17基因或蛋白在制备肺癌诊断及治疗药剂中的应用 | |
Li et al. | mRNA‐Lipid Nanoparticle‐Mediated Restoration of PTPN14 Exhibits Antitumor Effects by Overcoming Anoikis Resistance in Triple‐Negative Breast Cancer | |
CN116656682A (zh) | 一种galns抑制剂及其逆转鼻咽癌细胞生长的方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190830 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190830 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200804 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201005 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201007 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210413 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210413 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210413 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210603 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210608 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210823 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211005 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211025 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6973737 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |